Is PRA Health Sciences, Inc. (PRAH) a Buy? The Stock Reaches 52-Week High Today

June 16, 2018 - By Marry Poplack

PRA Health Sciences, Inc. (NASDAQ:PRAH) Logo

The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) hit a new 52-week high and has $100.80 target or 5.00 % above today’s $96.00 share price. The 9 months bullish chart indicates low risk for the $6.15B company. The 1-year high was reported on Jun, 16 by If the $100.80 price target is reached, the company will be worth $307.55 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.88% or $0.84 during the last trading session, reaching $96. About 988,592 shares traded or 53.90% up from the average. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 12.34% since June 16, 2017 and is uptrending. It has underperformed by 0.23% the S&P500.

Analysts await PRA Health Sciences, Inc. (NASDAQ:PRAH) to report earnings on August, 6. They expect $0.87 EPS, up 40.32 % or $0.25 from last year’s $0.62 per share. PRAH’s profit will be $55.74M for 27.59 P/E if the $0.87 EPS becomes a reality. After $0.78 actual EPS reported by PRA Health Sciences, Inc. for the previous quarter, Wall Street now forecasts 11.54 % EPS growth.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

Among 6 analysts covering PRA Health Sciences (NASDAQ:PRAH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. PRA Health Sciences had 7 analyst reports since January 18, 2018 according to SRatingsIntel. Robert W. Baird maintained PRA Health Sciences, Inc. (NASDAQ:PRAH) on Thursday, January 18 with “Buy” rating. As per Wednesday, January 24, the company rating was downgraded by Mizuho. The firm has “Buy” rating by SunTrust given on Monday, January 22. Jefferies maintained PRA Health Sciences, Inc. (NASDAQ:PRAH) rating on Thursday, February 22. Jefferies has “Buy” rating and $103.0 target. On Tuesday, January 30 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The firm has “Outperform” rating by Credit Suisse given on Thursday, February 22. The firm earned “Buy” rating on Monday, February 26 by SunTrust.

More important recent PRA Health Sciences, Inc. (NASDAQ:PRAH) news were published by: which released: “PRA Named International Clinical Research Company of the Year” on May 24, 2018, also published article titled: “PRAH +3% on MidCap 400 move; ABMD to S&P 500”, published: “Contract research giant plans new Lenexa lab” on June 04, 2018. More interesting news about PRA Health Sciences, Inc. (NASDAQ:PRAH) was released by: and their article: “4 Pharmaceutical Services Stocks To Buy With Big Upside Potential” with publication date: June 13, 2018.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $6.15 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 72.73 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: